Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
29 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsRoche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
(WorldNews Switzerland)

 
 

12 december 2017 15:14:18

 
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
(WorldNews Switzerland)
 


Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial Results will be presented during the Late-Breaking Abstracts Session at the 59th American Society of Hematology Annual Meeting Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first results from the pivotal phase III MURANO study evaluating VenclextaTM/VenclyxtoTM (venetoclax)...


 
16 viewsCategory: General > Europe > Switzerland
 
Reformed-Pentecostal dialogue focses on mission and ecclesiology
(WorldNews Switzerland)
A world-first: Sunrise and Huawei reach the fastest 5G connection in Switzerland
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten